Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound sirolimus injection combined with different ADCs in advanced solid tumors
CTR20254196Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus, DP303c, CRB-701, CPO301, SYS6043 in Nonhematologic neoplasms, breast cancer, triple-negative breast cancer (TNBC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Dec 2025; status: active.
02
Drugs
sirolimusDP303cCRB-701CPO301SYS6043
03
Conditions
Nonhematologic neoplasmsbreast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20254196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254196.